TON - December 2020, Vol 13, No 6

TON June 2020, Vol 13, No 3 Cover

Novel Drug Combinations Achieving Undetectable Minimal Residual Disease in Patients with CLL

By William King

TON - December 2020, Vol 13, No 6

Nivolumab New Standard of Care in Gastroesophageal Cancers as First-Line or Adjuvant Therapy

By Patricia Stewart

ESMO, ESMO 2020

TON - December 2020, Vol 13, No 6

Cabozantinib plus Nivolumab Offers New First-Line Treatment Option for Patients with Advanced Renal-Cell Carcinoma

By Patricia Stewart

ESMO, ESMO 2020

TON - December 2020, Vol 13, No 6

Olaparib Significantly Improves Survival in Men with Metastatic Prostate Cancer and BRCA Mutations

By Patricia Stewart

ESMO, ESMO 2020

TON - December 2020, Vol 13, No 6

“Practice-Changing” Results Seen with Adjuvant Abemaciclib plus Endocrine Therapy in HR-Positive, HER2-Negative Breast Cancer

By Patricia Stewart

ESMO, ESMO 2020

TON - December 2020, Vol 13, No 6

Opportunities for Innovation in Value-Based Payments in Oncology

Value-Based Care

TON - December 2020, Vol 13, No 6

Can We Lower the Cost of Cancer Care?

Value-Based Care

TON - December 2020, Vol 13, No 6

Personalized Vaccine plus Atezolizumab Shows Promising Clinical Activity in Advanced Cancer

By Patricia Stewart

TON - December 2020, Vol 13, No 6

Understanding Social Determinants of Health and Their Impact on Cancer Care

By Charlie Dawson

Quality Care Symposium

TON - December 2020, Vol 13, No 6

FDA NEWS December 2020

TON - December 2020, Vol 13, No 6

Page 2 of 3

1
2
3

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

TON Print Edition

TON Weekly e‑Newsletter

I have reviewed and consent to the terms of TON's Privacy Policy, and TON has my permission to retain my information in its database, and to forward pertinent communications to me.